Allergan takes Linzess on a run with differentiation push

Carly Helfand Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, ...

Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

Now focused on integrating Allergan generics, Teva eyes ‘much larger’ specialty buy in 2017

Carly Helfand SAN FRANCISCO–After watching months of pharma's M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan's ...

Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conference

Eric Palmer There are big questions facing some of pharma's key players this year, like whether the Pfizer and Allergan deal will get done and why Allergan thinks that is its best ...

Teva to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters

Carly Helfand Back in July, Teva agreed to pick up Allergan's generics business for $ 40.5 billion. To get that deal past regulators, though, it's going to have to divest some ...

Allergan CEO Saunders could cash out Pfizer deal with $187M, Bloomberg figures

Eric Palmer Even if Brent Saunders does not get the CEO role at Pfizer as a condition of Allergan agreeing to a buyout, which is reportedly being demanded, he will still get ...

Pfizer and Allergan wend toward a $150B merger, reports say

Tracy Staton Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $ 150 billion, at ...

Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott

Eric Palmer Allergan has been trying for months to resolve bribery allegations that came with its $ 8.5 billion buyout of Warner Chilcott and now will do that with a plea deal ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

Allergan recalls eye drugs after patients complain of particles, blurred vision

Carly Helfand Since Allergan and Actavis joined hands to become a new-look Allergan, the company has already had to recall a from the Actavis side. Now, it's recalling one from ...

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

Ackman’s ‘wolf pack’ drove Allergan into foreign hands, former CEO says

Carly Helfand Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. ...
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS